Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis.

Objectives: To identify biomarkers at the gene expression level to predict response to methotrexate (MTX) in patients with rheumatoid arthritis (RA).

Methods: MTX-naïve patients with RA were started on MTX and followed up over three months. The disease activity score 28 (DAS28) was used to classify patients into responders and non-responders.